Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study

被引:42
作者
Jordan, Ashly E. [1 ,3 ]
Masson, Carmen L. [2 ]
Mateu-Gelabert, Pedro [3 ,4 ]
McKnight, Courtney [1 ,3 ]
Pepper, Nicole [2 ]
Bouche, Katie [5 ]
Guzman, Laura [6 ]
Kletter, Evan [7 ]
Seewald, Randy M. [1 ]
Des-Jarlais, Don C. [1 ,3 ]
Sorensen, James L. [2 ]
Perlman, David C. [1 ,3 ]
机构
[1] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
[2] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Psychiat, San Francisco, CA 94110 USA
[3] Ctr Drug Use & HIV Res, New York, NY 10003 USA
[4] Natl Dev & Res Inst Inc, New York, NY 10010 USA
[5] San Francisco AIDS Fdn, HIV Prevent Project, San Francisco, CA 94103 USA
[6] Mission Neighborhood Resource Ctr, San Francisco, CA 94110 USA
[7] BAART Programs, San Francisco, CA 94102 USA
关键词
Hepatitis C; Illicit drug use; Injection drug use; Health care access; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; GLOBAL EPIDEMIOLOGY; HCV INFECTION; BARRIERS; KNOWLEDGE; ATTITUDES; RISK; METAANALYSIS; ERADICATION;
D O I
10.1186/1477-7517-10-10
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Illicit drug users have a high prevalence of HCV and represent the majority of newly infected persons in the U. S. Despite the availability of effective HCV treatment, few drug users have been evaluated or treated for HCV. Racial and ethnic minorities have a higher incidence and prevalence of HCV and higher HCV-related mortality. Factors contributing to poor engagement in care are incompletely understood. Methods: Fourteen mixed-gender focus groups of either African American or Latino/a drug users (N = 95) discussed barriers to HCV testing and treatment. Themes were identified through content analysis of focus group discussions. Results: Many drug users were tested for HCV in settings where they were receiving care. Outside of these settings, most were unaware of voluntary test sites. After testing HCV positive, drug users reported not receiving clear messages regarding the meaning of a positive HCV test, the impact of HCV infection, or appropriate next steps including HCV clinical evaluations. Many drug users perceived treatment as unimportant because they lacked symptoms, healthcare providers minimized the severity of the diagnosis, or providers did not recommend treatment. Mistrust of the motivations of healthcare providers was cited as a barrier to pursuing treatment. Social networks or social interactions were a source of HCV-related information and were influential in shaping drug users perceptions of treatment and its utility. Conclusion: Drug users perceived a paucity of settings for self-initiated HCV testing and poor provider-patient communication at test sites and during medical encounters. Notably, drug users reported having an unclear understanding about the meaning of a positive HCV test, the health implications of HCV infection, the importance of clinical evaluations and monitoring, and of treatment options for HCV. Efforts to improve the delivery of clinical messages about HCV infection for drug users at test settings and clinical encounters are needed.
引用
收藏
页数:8
相关论文
共 44 条
  • [1] Global estimates of prevalence of HCV infection among injecting drug users
    Aceijas, Carmen
    Rhodes, Tim
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) : 352 - 358
  • [2] Epidemiology of hepatitis C virus infection
    Alter, Miriam J.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) : 2436 - 2441
  • [4] [Anonymous], HEP C
  • [5] Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C
    Broers, B
    Helbling, B
    François, A
    Schmid, P
    Chuard, C
    Hadengue, A
    Negro, F
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (03) : 323 - 328
  • [6] Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients
    Bruggmann, P.
    Falcato, L.
    Dober, S.
    Helbling, B.
    Keiser, O.
    Negro, F.
    Meili, D.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 (10) : 747 - 752
  • [7] Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City
    Des Jarlais, DC
    Diaz, T
    Perlis, T
    Vlahov, D
    Maslow, C
    Latka, M
    Rockwell, R
    Edwards, V
    Friedman, SR
    Monterroso, E
    Williams, I
    Garfein, RS
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 157 (05) : 467 - 471
  • [8] Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States
    Deuffic-Burban, S.
    Poynard, T.
    Sulkowski, M. S.
    Wong, J. B.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2007, 14 (02) : 107 - 115
  • [9] Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia
    Doab, A
    Treloar, C
    Dore, GJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 : S313 - S320
  • [10] Injection drug users: The overlooked core of the hepatitis C epidemic
    Edlin, BR
    Carden, MR
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (05) : 673 - 676